HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit an electronic Letter to the Editor about this paper Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (3) Citing Articles via Google Scholar Google Scholar Articles by Sölétormos, G. Articles by Schiøler, V. Search for Related Content PubMed PubMed Citation Articles by Sölétormos, G. Articles by Schiøler, V. Related Collections Laboratory Management Proteomics and Protein Markers

Description of a Computer Program to Assess Cancer Antigen 15.3, Carcinoembryonic Antigen, and Tissue Polypeptide Antigen Information during Monitoring of Metastatic Breast Cancer

¹ Department of Clinical Biochemistry, Herlev Hospital, University of Copenhagen, DK-2700 Copenhagen, Denmark and

² Oncology, Herlev Hospital, University of Copenhagen, DK-2700 Copenhagen, Denmark.

³ Department of Clinical Biochemistry, Hillerød Hospital, DK 3400 Hillerød, Denmark.
^a Address correspondence to this author at: Department of Clinical Biochemistry, Hillerød Hospital, Helsevej 2, DK 3400 Hillerød, Denmark. Fax 45-4824-0067; e-mail geso{at}fa.dk

It is time-consuming to process and compare the clinical and marker information registered during monitoring of breast cancer patients. To facilitate the assessment, we developed a computer program for interpreting consecutive measurements. The intraindividual biological variation, the analytical precision profile, the cutoff limit, and the detection limit for each marker are entered and stored in the program. The assessment procedure for marker signals considers the analytical and biological variation of the applied markers. The software package contains a database that can store the interpretation of the measurements as evaluation codes together with patient demographics, information about treatment type, dates for treatment periods, control periods, and evaluation codes for clinical activity of disease. The consecutive concentrations for a patient are imported temporarily into the program from outside sources and presented graphically. Marker concentrations to be compared are selected with the computer mouse and the significance of the difference is calculated by the program. The program has an option for calculating the lead time of marker signals vs clinical information. The program facilitates the monitoring of individual breast cancer patients with tumor marker measurements. It may also be implemented in trials investigating the utility of potential new markers in breast cancer as well as in other malignancies.

The following articles in journals at HighWire Press have cited this article:

				G. Soletormos, A. Semjonow, P. E.C. Sibley, R. Lamerz, P. H. Petersen, W. Albrecht, P. Bialk, M. Gion, F. Junker, H.-P. Schmid, et al. Biological Variation of Total Prostate-Specific Antigen: A Survey of Published Estimates and Consequences for Clinical Practice Clin. Chem., August 1, 2005; 51(8): 1342 - 1351. [Abstract] [Full Text] [PDF]